Systematic review with network meta‐analysis: the impact of medical interventions for moderate‐to‐severe ulcerative colitis on health‐related quality of life
Open Access
- 30 October 2018
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 48 (11-12), 1174-1185
- https://doi.org/10.1111/apt.15005
Abstract
Background Patient‐reported outcomes are important in the assessment of efficacy of intervention for ulcerative colitis (UC). Aim To compare the impact of interventions for moderate‐to‐severe UC on health‐related quality of life (HRQL). Methods We searched Medline, Embase, CENTRAL and grey literature sources through October 2017. We included randomised controlled trials (RCTs) that compared infliximab, adalimumab, golimumab, vedolizumab or tofacitinib to each other or placebo. Outcomes included the change in quality of life scores and the proportion of patients with improvement in quality of life. We performed random‐effect pairwise and network meta‐analysis. We assessed confidence in estimates using the CINeMA (Confidence in Network Meta‐Analysis) framework. Results Fourteen RCTs assessed HRQL using the Inflammatory Bowel Disease Questionnaire (IBDQ) (14 trials), the Short Form questionnaire‐36 (SF‐36) (seven trials) or the European Quality of Life‐5 Dimensions questionnaire (EQ‐5D) (three trials). At induction (13 trials), low to very low confidence evidence suggested that all agents significantly improved both generic and disease‐specific HRQL scores compared to placebo. However, only infliximab (MD 18.58; 95% CI 13.19‐23.97) and vedolizumab (MD 18.00; 95% CI 11.08‐24.92) showed clinically meaningful improvement in IBDQ score. Differences among individual interventions were imprecise. For maintenance (four trials), very low confidence evidence suggested that vedolizumab, tofacitinib and adalimumab maintained improvement in HRQL. Conclusions Induction treatment with infliximab, adalimumab, golimumab, vedolizumab or tofacitinib improves quality of life compared to placebo. Evidence on maintenance therapy is sparse and uncertain. Head‐to‐head comparisons could enhance confidence in conclusions about differences between drugs in terms of HRQL.Keywords
This publication has 37 references indexed in Scilit:
- Graphical Tools for Network Meta-Analysis in STATAPLOS ONE, 2013
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2013
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative ColitisNew England Journal of Medicine, 2012
- Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic ReviewsInternational Journal of Epidemiology, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut, 2011
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorialJournal of Clinical Epidemiology, 2010
- Checking consistency in mixed treatment comparison meta‐analysisStatistics in Medicine, 2010
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987